AGO1 antibody: RN028PW


Antibody Info
Product_IDRN028PW
Lot_ID2
Host_organismrabbit
SourceMBLI
Antibody_DCC_IDENCAB179WCQ
Target Info
GeneNameAGO1
Phosphate
Target_nameAGO1-human

Validation Images
Cell linePrimary validationSecondary validation
HepG2 EIF2C1-HEPG2-RN028PW.png<br>Caption: Western blot following shRNA against AGO1/EIF2C1 in HepG2 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.

Caption: Western blot following shRNA against AGO1/EIF2C1 in HepG2 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.

Releated Sample: BGHLV14-13

Status: Released

Lab: Graveley Lab

K562 K562_MBLI_RN028PW_002_EIF2C1.png<br>Caption: IP-WB characterization of AGO1 specific antibody in K562 cell line . Lane 1 is 2.5% of five million K562 whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-EIF2C1(AGO1)(Human)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.

Caption: IP-WB characterization of AGO1 specific antibody in K562 cell line . Lane 1 is 2.5% of five million K562 whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-EIF2C1(AGO1)(Human)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.

Method: immunoprecipitation

Status: Released

Lab: Yeo Lab

EIF2C1-k562-RN028PW.png<br>Caption: Western blot following shRNA against EIF2C1 in K562 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.

Caption: Western blot following shRNA against EIF2C1 in K562 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.

Releated Sample: BGKLV13-69

Status: Released

Lab: Graveley Lab

EIF2C1_Secondary_Western.png<br>Caption: Western blot following shRNA against AGO1 in K562 whole cell lysate using AGO1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNA against AGO1. AGO1 protein appears as the green arrow, Tubulin serves as a control and appears in red arrow.

Caption: Western blot following shRNA against AGO1 in K562 whole cell lysate using AGO1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNA against AGO1. AGO1 protein appears as the green arrow, Tubulin serves as a control and appears in red arrow.

Releated Sample: BGKLV13-69

Status: NotSatisfied

Lab: Graveley Lab